[Perftoran in the endotoxicosis correction in purulent-inflammatory urological diseases].
Perftoran (PF) was used within a complex intensive care of 74 patients with purulent-inflammatory urological diseases and with signs of generalized inflammation. Positive effects were found to be made by PF on the parameters of microcirculation, oxygen status, dynamics of the serum content of cytokines, condition of their balance and immune status, which entailed a regression of endogenous intoxication and arrested the inflammatory lesion in the kidneys. PF cut the intensive care time of patients with complicated urological infection by 4.2+/-0.4 days (p < 0.05). The conclusion is that PF is a novel pathogenetic treatment method applicable to patients with purulent-inflammatory urological diseases.
Ushakova
N D
ND
Moroz
V V
VV
Andreeva
I I
II
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood; D019446:Endotoxemia / Q000188:drug therapy*; D005466:Fluorocarbons / Q000494:pharmacology / Q000627:therapeutic use*; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D008833:Microcirculation / Q000187:drug effects; D013492:Suppuration / Q000150:complications / Q000188:drug therapy
D016207:Cytokines; D005466:Fluorocarbons; C063334:perftoran